Company: ZVRA
Filing Date: 2025-03-31
Form Type: PREC14A
Source: 0001193125-25-068746
Chunk: 38

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: PREC14A
Chunk 38
---
 only our independent directors were present.

<div align='center'>34</div>

Information Regarding Committees of the Board The Board has three committees: the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. The following table provides current membership for each of the Board committees and the 2024 meeting information for each of the Board committees.

| Name                   |     | Audit |     | Compensation |     | Nominating and Corporate Governance |
| Thomas D. Anderson     |     |       |     |           X* |     |                                   X |
| John B. Bode           |     |     X |     |              |     |                                  X* |
| Douglas W. Calder      |     |       |     |            X |     |                                     |
| Wendy Dixon, Ph.D.     |     |     X |     |              |     |                                     |
| Tamara A. Favorito     |     |    X* |     |              |     |                                     |
| Neil F. McFarlane      |     |       |     |              |     |                                     |
| Alvin Shih, M.D.       |     |       |     |            X |     |                                   X |
| Corey Watton           |     |     X |     |            X |     |                                     |
| Total meetings in 2024 |     |     5 |     |            4 |     |                                   4 |

*Committee Chair

| BELOW IS A DESCRIPTION OF EACH COMMITTEE OF THE BOARD. |

Audit Committee The Audit Committee reviews our internal accounting procedures and consults with and reviews the services provided by our independent registered public accounting firm. Our Audit Committee consists of four directors, John B. Bode, Wendy Dixon, Ph.D., Tamara A. Favorito and Corey Watton. Our Board has determined that each of Mr. Bode, Dr. Dixon, Ms. Favorito and Mr. Watton are independent directors under Nasdaq listing rules and under Rule 10A 3 under the Exchange Act. Ms. Favorito is the chair of the Audit Committee. Our Board has determined that each of Ms. Favorito and Mr. Bode is considered to be an “audit committee financial expert,” as defined by SEC rules and regulations, following a qualitative assessment of their level of financial expertise, knowledge and experience based on a number of factors including their previous business experience as described above, respectively, under the sections titled “Nominees for Election as a Class I Director for a